 TEL AVIV, Israel and BETHESDA, Maryland, June 17, 2021 PRNewswire -- Cannabics Pharmaceuticals Inc. OTCQB: CNBX, a global leader in the development of cancer related cannabinoid-based medicine, announced today the expansion of its research program with new drug development projects targeting Prostate Cancer, Neurodegenerative Mental Health diseases. The announcement of the new research projects follows promising initial preclinical results obtained in the companys in-house drug discovery facility in Rehovot, Israel. 